Crizotinib in Advanced Lung Adenocarcinoma Patients with ALK or ROS-1 Rearrangement: Is it the Same?

被引：0
作者：
Han, B. [1 ]
Zhang, B. [1 ]
Xu, J. [1 ]
Zhang, Y. [1 ]
Zhang, X. [1 ]
Chu, T. [1 ]
Wang, S. [1 ]
Qiao, R. [1 ]
Qian, J. [1 ]
Lu, J. [1 ]
Zhang, L. [1 ]
机构：
[1] Shanghai Chest Hosp, Shanghai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期
关键词：
ALK; ros1; crizotinib;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.01-29
引用
收藏
页码：S471 / S471
页数：1
相关论文
共 50 条
  • [41] A novel SOS1-ALK fusion variant in a patient with metastatic lung adenocarcinoma and a remarkable response to crizotinib
    Chen, Hua-fei
    Wang, Wen-xian
    Xu, Chun-wei
    Huang, Li-chao
    Li, Xiao-feng
    Lan, Gang
    Zhai, Zhan-qiang
    Zhu, You-cai
    Du, Kai-qi
    Lei, Lei
    Fang, Mei-yu
    LUNG CANCER, 2020, 142 : 59 - 62
  • [42] Comprehensive analysis of RET and ROS1 rearrangement in lung adenocarcinoma
    Lee, Seung Eun
    Lee, Boram
    Hong, Mineui
    Song, Ji-Young
    Jung, Kyungsoo
    Lira, Maruja E.
    Mao, Mao
    Han, Joungho
    Kim, Jhingook
    Choi, Yoon-La
    MODERN PATHOLOGY, 2015, 28 (04) : 468 - 479
  • [43] Case Report: Detection of Double ROS1 Translocations, SDC4-ROS1 and ROS1-GK, in a Lung Adenocarcinoma Patient and Response to Crizotinib
    Xu, Long
    Chen, Xiaoxia
    Huo, Hong
    Liu, Yongye
    Yang, Xiaodan
    Gu, Dejian
    Yuan, Mingming
    Zhang, Min
    Chen, Rongrong
    Wang, Jiayin
    Zheng, Zhendong
    FRONTIERS IN MEDICINE, 2021, 8
  • [44] EUCROSS: A European Phase II Trial of Crizotinib in Advanced Adenocarcinoma of the Lung Harboring ROS1 Rearrangements - Preliminary Results
    Michels, Sebastian
    Gardizi, Masyar
    Schmalz, Petra
    Thurat, Meike
    Pereira, Eva
    Sebastian, Martin
    Carcereny, Enric
    Corral, Jesus
    Paz-Ares, Luis
    Felip, Enriqueta
    Grohe, Christian
    Rodriguez Abreu, Delvys
    Insa Molla, Amelia
    Bischoff, Helge
    Reck, Martin
    Karachaliou, Niki
    Scheel, Andreas
    Brandes, Vanessa
    Rieke, Fischer
    Nogova, Lucia
    Scheffler, Matthias
    Franklin, Jeremy
    Hellmich, Martin
    Massuti, Bartomeu
    Buettner, Reinhard
    Rosell, Rafael
    Wolf, Juergen
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S379 - S380
  • [45] Identification of ROS1 Rearrangement in Gastric Adenocarcinoma
    Lee, Jeeyun
    Lee, Seung Eun
    Kang, So Young
    Do, In-Gu
    Lee, Sujin
    Ha, Sang Yun
    Cho, Jeonghee
    Kang, Won Ki
    Jang, Jiryeon
    Ou, Sai-Hong Ignatius
    Kim, Kyoung-Mee
    CANCER, 2013, 119 (09) : 1627 - 1635
  • [46] ALK-Rearrangement May Promote VTE by Increasing the Expression of TF in Advanced Lung Adenocarcinoma
    Yang, S.
    Wang, Q.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S655 - S655
  • [47] Successful Desensitization with Crizotinib after Crizotinib-induced Liver Injury in ROS1-rearranged Lung Adenocarcinoma
    Ota, Takayo
    Masuda, Noriyuki
    Matsui, Kaoru
    Yamada, Takao
    Tanaka, Noriko
    Fujimoto, Shunsuke
    Fukuoka, Masahiro
    INTERNAL MEDICINE, 2019, 58 (18) : 2651 - 2655
  • [48] Elevation of tumor mutation burden in ROS1-fusion lung adenocarcinoma resistant to crizotinib A case report
    Yang, Tao
    Xu, Rui
    Yan, Bing
    Li, Fang
    Liu, Hui
    MEDICINE, 2018, 97 (52)
  • [49] Advanced lung adenocarcinomas with ROS1-rearrangement frequently show hepatoid cell
    Zhao, Jing
    Zheng, Jing
    Kong, Mei
    Zhou, Jianya
    Ding, Wei
    Zhou, Jianying
    ONCOTARGET, 2016, 7 (45) : 74162 - 74170
  • [50] Efficacy and safety of crizotinib plus bevacizumab in ALK/ROS-1/c-MET positive non-small cell lung cancer: an open-label, single-arm, prospective observational study
    Huang, Ziwei
    Xiong, Qi
    Cui, Zhi
    Tao, Haitao
    Zhang, Sujie
    Wang, Lijie
    Cui, Pengfei
    Chen, Shixue
    Huang, Di
    Yang, Bo
    Hu, Yi
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2021, 13 (03): : 1526 - 1534
12345